(19)
(11) EP 1 162 272 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 2 (W2 B1)

(48) Corrigendum issued on:
10.03.2010 Bulletin 2010/10

(45) Mention of the grant of the patent:
05.11.2008 Bulletin 2008/45

(21) Application number: 01113517.5

(22) Date of filing: 26.06.1996
(51) International Patent Classification (IPC): 
C12N 15/57(2006.01)
C12N 15/86(2006.01)
A61K 38/43(2006.01)
 C12N 9/64(2006.01)
C07K 16/30(2006.01)

(54)

Generation of immune responses to prostate-specific antigen (PSA)

Herstellung von einer Immunantwort gegen Prostat-spezifisches Antigen (PSA)

Génération de réponses immunitaires à l'antigène spécifique de la prostate (PSA)

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 10.07.1995 US 500306

(43) Date of publication of application:
12.12.2001 Bulletin 2001/50

(62) Application number of the earlier application in accordance with Art. 76 EPC:
96923417.8 / 0840791

(73) Proprietor: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
Rockville, MD 20852 (US)

(72) Inventors:
  • Schlom, Jeffrey National Cancer Institute
    Bethesda, Maryland 20892 (US)
  • Panicali, Dennis, Therion Biologics Corporation
    Cambridge, Massachusetts 02142 (US)

(74) Representative: Brown, David Leslie et al
Haseltine Lake LLP Redcliff Quay 120 Redcliff Street
Bristol BS1 6HU
Bristol BS1 6HU (GB)


(56) References cited: : 
EP-A- 0 652 014
WO-A-95/04548
 EP-A- 0 725 139
ZA-A- 9 401 645
   
  • HODGE J W ET AL: "A recombinant vaccinia virus expressing human prostate - specific antigen (PSA): Safety and immunogenicity in a non-human primate." INTERNATIONAL JOURNAL OF CANCER 63 (2). 1995. 231-237. ISSN: 0020-7136, XP000605674
  • CORMAN J M ET AL: "Prostate specific antigenic peptides induce T - cell proliferation in-vitro: A model for the development of prostate specific tumor vaccines." NINETY-FIRST ANNUAL MEETING OF THE AMERICAN UROLOGY ASSOCIATION, ORLANDO, FLORIDA, USA, MAY 4-9, 1996. JOURNAL OF UROLOGY 155 (5 SUPPL.). 1996. 528A. ISSN: 0022-5347, XP000604547
  • CORRELAE P ET AL: "Generation of human T - cell lines specific for prostate specific antigen using an oligo-epitope peptide." 87TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, WASHINGTON, D.C., USA, APRIL 20-24, 1996. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 37 (0). 1996. 488-489. ISSN: 0197-016X, XP002018984
  • LU, EDWARD W. ET AL: "Factors affecting production of antibodies to prostate antigens by in vitro-primed human splenocytes" HYBRIDOMA (1993), 12(4), 381-9 CODEN: HYBRDY;ISSN: 0272-457X, 1993, XP000605666
  • P. CORREALE ET AL.: "In vitro stimulation of human cytotoxic T lymphocytes specific for peptides derived from prostate specific antigen." 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY, no. 3449, 1 January 1995 (1995-01-01), page 582, XP000607089
  • J. KANTOR ET AL.: "Immunogenicity and safety of a recombinant Vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate." CANCER RESEARCH, vol. 52, 15 December 1992 (1992-12-15), pages 6917-6925, XP000605381
  • ABULAFIA R ET AL: "IN-VITRO PRODUCTION OF T CELLS IMMUNOREACTIVE AGAINST PROSTATE SPECIFIC ANTIGEN A NOVEL APPROACH FOR AN ANTIGEN - SPECIFIC ADOPTIVE IMMUNOTHERAPY PROGRAM FOR PROSTATE CANCER." JOINT MEETING OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, AND THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, NEW ORLEANS, LOUISIANA, USA, JUNE 4-7, 1990. FASEB (FED AM SOC EXP BIOL) J 4 (7). 1990. A2021. CODEN: FAJOEC ISSN: 0892-6638, XP002018985
  • ROSS S ET AL: "Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): Results from a pilot study." BIOTECHNOLOGY THERAPEUTICS 4 (3-4). 1993. 197-211. ISSN: 0898-2848, XP000605665
  • E. PAOLETTI ET AL.: "Immunotherapeutic stategies for cancer using poxvirus vectors." ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 690, 1993, pages 292-300, XP000605669
  • J.F. DONOVAN ET AL.: "Immunotherapy of prostate cancer." PROBLEMS IN UROLOGY, vol. 4, no. 3, September 1990 (1990-09), pages 489-505, XP000604543
  • KAUFMAN H.L. ET AL: 'Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group.' JOURNAL OF CLINICAL ONCOLOGY vol. 22, no. 11, 01 June 2004, pages 2122 - 2132
  • KAUFMAN H.L. ET AL: 'Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: Follow-up clinical results from ECOG 7897' JOURNAL OF CLINICAL ONCOLOGY vol. 23, no. 16S, 01 June 2005, page 4501
  • MARSHALL J.L. ET AL: 'Phase I study in cacner patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.' JOURNAL OF CLINICAL ONCOLOGY vol. 17, no. 1, 1999, pages 332 - 337
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).